Dr. Kieron Dunleavy, MD

Dr. Dunleavy practices at Medstar Georgetown Medical Center in Washington, District of Columbia.

Dr. Dunleavy's NPI, 1154610467, was assigned on April 7, 2011. Dr. Dunleavy holds District of Columbia license MD045060.

Dr. Dunleavy's primary practice is Medstar Georgetown Medical Center, at 3800 Reservoir NW Rd, Washington, DC 20007 in District Of Columbia County. The practice phone is (202) 444-1400.

Dr. Dunleavy's primary practice is Medstar Georgetown Medical Center in Washington, District of Columbia. Dr. Dunleavy is also affiliated with MedStar Washington Hospital Center. The medical group on file is MedStar Medical Group. Dmand AI also links Dr. Dunleavy to 1 more hospital, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dunleavy practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dunleavy's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dunleavy is licensed in District of Columbia.

CMS data shows 859 Medicare services from Dr. Dunleavy across 7 procedure codes in 2024, for 198 Medicare patients. Medicare paid $68,367 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 198 Medicare patients who saw Dr. Dunleavy in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dunleavy's median patient age at 63, with 46% women.

In 2024, Dr. Dunleavy wrote 115 Medicare Part D claims for 28 patients. CMS names the drug for 72 of them, across 3 drugs with 11 or more claims each, at $1,344,937 in total drug cost. In 2023, CMS named 29 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Dunleavy for performance year 2024. Dr. Dunleavy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dunleavy as offering telehealth.

Dmand AI links 96 papers to Dr. Dunleavy, published from 2010 to 2025. 2016 was the busiest year, with 5. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols and Doxorubicin. Dr. Dunleavy has published most often in Blood. Dr. Dunleavy's most frequent co-authors are Wyndham Hopkins Wilson, MD, PhD, Mark Jason Roschewski, MD and Christopher Joseph Melani, MD.

Dmand AI links Dr. Dunleavy to 3 clinical trials, 2 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include HIV Infections, Lymphoma, Follicular and Tumor Lysis Syndrome.

CMS Open Payments shows 156 general payments to Dr. Dunleavy from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Amgen Inc. paid the most, $25,292.